Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tyrosine-protein kinase receptor FLT3 (FLT3) is a receptor tyrosine kinase that plays a crucial role in hematopoiesis, regulating the differentiation, proliferation, and survival of hematopoietic progenitor cells. Mutations in FLT3, particularly internal tandem duplications (FLT3-ITD) and point mutations at D835, are common in acute myeloid leukemia (AML) and drive uncontrolled proliferation and resistance to apoptosis. FLT3 is a therapeutic target, and FLT3 inhibitors have been developed for AML treatment.
Inhibition of FLT3 kinase activity, either by binding to the ATP-binding site (Type I) or preventing activation by occupying a hydrophobic region (Type II).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tyrosine-protein kinase receptor FLT3 (FLT3).